Articles tagged with Leukemia
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
A new study published in the Lancet Haematology found that children with Down syndrome are more likely to develop aggressive forms of leukemia and have a poorer prognosis. The research also identified potential differences in treatment outcomes between children with and without Down syndrome.
Researchers at the University of Basel have discovered a novel combination therapy approach that combines inhibiting JAK2 with targeting the MAPK signaling pathway. This dual targeting strategy has shown promising results in improving leukemia treatment outcomes by reducing blood cell production and altering disease course.
Children genetically predisposed to overproduce lymphocytes in relation to other white blood cells are at higher risk of developing ALL, according to a new USC study. The research found that the ratio of lymphocytes to other key blood cells is significant in predicting leukemia risk.
Researchers found no significant DNA changes in stem cells after transplant, but an anti-virus drug called ganciclovir may contribute to cancer development. Further research is needed to investigate this further.
A study from Linköping University found that the tumour-inhibiting gene TET2 is silenced in most cases of acute lymphoblastic leukemia (ALL) in children. The gene can be reactivated by treatment with an existing drug, 5-azacytidine, suggesting a targeted therapy for ALL in children.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
A large phase 3 noninferiority clinical trial showed that omitting pulse therapy in patients with low-risk disease improves quality of life without affecting survival. This finding is significant as it reduces neuropsychological side effects and late effects associated with long-term treatment.
Researchers have discovered protein markers related to chronic lymphocytic leukemia (CLL), a common form of leukemia. The markers can help determine patients' prognoses and point to potential therapeutic targets.
Researchers in China have created a novel risk score to predict relapse of leukemia, allowing for better medical intervention and stratification of patients with different risks. The study analyzed factors such as engraftment of white blood cells, residual cancer cells, and chronic graft-versus-host disease to determine outcomes like 5...
Researchers at University of Texas M. D. Anderson Cancer Center found that combination ibrutinib and venetoclax provided lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), with a three-year overall survival rate of 96%
A team of researchers has developed first-in-class small molecules to inhibit the SET domain of the ASH1L protein, preventing critical molecular interactions in leukemia development. The lead compound, AS-99, successfully reduced leukemia progression in mouse models.
Researchers at Johns Hopkins Medicine used information theory to identify a likely key genetic culprit in acute lymphoblastic leukemia (ALL), the most common form of childhood leukemia. By analyzing DNA methylation patterns, they discovered a gene called UHRF1 that drives the development of cancer.
Researchers at Tokyo Medical and Dental University developed an antibody-drug conjugate that selectively targets human monocyte progenitors to combat chronic myelomonocytic leukemia (CMML). This strategy effectively blocks malignant cell proliferation with minimal collateral damage to other cell lineages.
A low-calorie diet and moderate exercise program have been shown to dramatically improve survival outcomes for young people with acute lymphoblastic leukemia. After just one month of treatment, participants on the intervention had a 70% decrease in detectable cancer cells compared to those not on the regimen.
Researchers found that genetic mutations, such as IKZF1 deletion and CRLF2 translocations, occur more frequently in Hispanic and Latino children with B-cell acute lymphoblastic leukemia (B-ALL), leading to poorer outcomes. A novel therapeutic drug combination may help address this disparity.
A novel metabolic gatekeeper mechanism for leukemia has been discovered by Yale researchers, highlighting the importance of glucose and energy supply in leukemic transformation. High expression levels of PON2 enable glucose uptake activity in B-cell acute lymphoblastic leukemia cells, leading to a more aggressive course of disease.
Researchers have discovered that two anti-viral enzymes, APOBEC3C and ADAR1, fuel the transition from pre-cancer stem cells to leukemia stem cells. Inhibiting these enzymes with existing medications may help prevent cancer, including leukemia.
The study showed that the combination of chemotherapy and blinatumomab resulted in increased survival rates and achieved a high rate of MRD negativity for patients with Ph-negative B-cell ALL. This treatment approach has the potential to improve long-term outcomes for these patients.
A study by Octapharma at ASH found that high-dose Octagam 10% IVIg significantly improved hypoxia and reduced hospital length of stay in COVID-19 patients with pneumonia. A larger multicenter study is underway to determine if the therapy can slow or stop respiratory deterioration.
MUSC researchers discovered blocking an energy pathway for T-cells after hematopoietic stem cell transplant reduces graft-versus-host disease, while maintaining ability to kill leukemia cells. The study uses a lysosomal acid lipase-deficient mouse model, showing promising results with FDA-approved inhibitor orlistat.
Researchers have identified a new and evolutionarily conserved pathway responsible for silencing genes in mammalian cells. BAHCC1 protein is involved in the Polycomb pathway, which generates a chemical tag to silence genes, and its high expression is linked to leukemia, challenging current understanding of gene silencing.
Researchers have developed a new type of precise therapeutic vaccine against leukemia utilizing self-healing polylactic acid microcapsules. The vaccine co-encapsulates a new epitope peptide and PD-1 antibody, demonstrating superior performance over commercialized adjuvants in various models.
Researchers at Temple University Health System discovered a mechanism behind drug resistance in leukemia cells and found that combining PARP inhibition with TGFBR kinase blockade can overcome resistance. This breakthrough could lead to a new treatment strategy for leukemia patients.
Researchers identified a second path to defeating chronic myelogenous leukemia by disrupting the Gdpd3 gene, which regulates quiescence of CML stem cells. This approach reduces leukemia relapse rates even when BCR-ABL1 oncogene is not disrupted.
Scientists have identified new genes that are overexpressed in endothelial cells of people with Down syndrome, increasing their risk for leukemia. The study suggests these genes could be therapeutic targets for developing novel treatments and prevention strategies.
A study published in Nature found that blood cell mutations linked to leukemias become inevitable as people age, especially in the Japanese population. The research identified genetic variations associated with increased risk of these mutations, which can be detected through a simple blood test.
UConn researchers use patented nanoparticle with common chemotherapy drug doxorubicin to target leukemia stem cells, reducing treatment-resistant relapses. The nanoparticle enables slow release of the drug to bone marrow, improving survival rates and inhibiting cancerous stem cells.
Scientists create super-powered natural killer cells by deleting an inhibitory gene, resulting in improved anti-tumor activity and persistence. The modified cells also exhibit enhanced metabolic reprogramming and energy utilization, leading to more effective cancer treatment.
The E1912 trial showed that the ibrutinib-rituximab combination provided better leukemia control, prolonged life, and had fewer side effects compared to standard care in untreated patients with chronic lymphocytic leukemia. The FDA approval is based on data from the phase 3 trial developed by the ECOG-ACRIN Cancer Research Group.
Scientists have engineered T-cells to target multiple sites on leukemia cells, offering a more effective treatment for resistant acute lymphoblastic leukemia. The new CAR-T therapy, TriCAR T-cells, targeting CD-19/20/22, demonstrate improved efficacy compared to single-antigen therapies.
Researchers found that structural changes in protein bundles called chromosomes affect access to genes in T cell acute lymphoblastic leukemia. The new work shows that altering the 3D architecture of chromosomes can trigger cancer growth and spread, making targeted therapy a promising approach.
Researchers at Nemours have identified new genetic structural variants in childhood leukemia that can help assess minimal residual disease during chemotherapy. This breakthrough could lead to more precise diagnosis and targeted therapies for kids with cancer, improving treatment outcomes.
Researchers identified subpopulations of leukemia cells present at diagnosis that have distinct characteristics, leading to relapse in children and adults. These findings provide new avenues for overcoming resistance and improving treatment approaches.
The CD19 CAR NK-cell therapy achieved a 73% response rate in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities reported. The treatment was administered in an outpatient setting, and responses were evident within one month following infusion.
Chronic lymphocytic leukemia (CLL) patients respond differently to ibrutinib treatment due to individual genetic and epigenetic profiles. The study reveals a shared genetic program in CLL cells responding to ibrutinib, but with patient-specific execution, leading to varying disease progression rates.
A collaborative clinical trial has led to changes in the treatment of leukemia driven by the Philadelphia chromosome, a high-risk subtype associated with poor outcomes. Dasatinib was found to provide greater benefit than the standard of care, resulting in improved event-free survival rates.
Researchers have identified a promising drug candidate OT-82 that demonstrates remarkable efficacy in preclinical models. It targets the NAMPT enzyme responsible for NAD production, showing potential as a novel treatment option for refractory blood cancers.
The E1912 follow-up analysis shows that ibrutinib-based therapy lived longer and with sustained benefit in previously untreated CLL patients. The majority of patients were well-tolerated, with only 14% stopping due to side effects.
Researchers at the University of Zurich have identified a new target for treating incurable leukemia in children by analyzing the molecular causes of the disease. They found that an abnormal protein activates genes at the wrong time, triggering the formation of malignant white blood cells and causing leukemia.
A new study found exposure to CT scans is associated with higher risks of developing thyroid cancer and leukemia. The risk is stronger in patients who have received multiple scans, particularly younger adults and females.
A clinical trial at St. Jude Children's Research Hospital found that adding chemotherapy doses in the cerebrospinal fluid improved CNS control without increasing toxicity for high-risk patients. The study reduced CNS relapse rates from 5.7% to 1.8%, making it the lowest among reported studies.
A months-old infant with rare childhood leukemia was treated with sorafenib, a targeted therapy approved for adults with inoperable liver cancer. The patient's unique genetic mutation led to a significant response to the treatment, highlighting the importance of identifying genetic mutations in cancer treatment.
Researchers have identified a potential combination targeted therapy for a deadly type of leukemia found in some infants, which was linked to high levels of the BCL6 protein and poor outcomes. The therapy involves 'turning off' the BCL6 protein using ABT-199, promising a lifesaving treatment option for babies and young children.
Researchers sequenced biopsies from pediatric patients with acute lymphoblastic leukemia and found that they harbored T cells specific to many neoepitopes. The patients' T cells responded to a significant proportion of these neoepitopes, forming hierarchies in their responses.
Researchers found that the combination of ibrutinib and venetoclax was highly effective in achieving complete remission with undetectable minimal residual disease in high-risk CLL patients. The study also showed that this combination therapy had no new toxic effects compared to individual agents.
A study by Maxime Caru found that childhood ALL survivors have significantly worse cardiorespiratory fitness than healthy Canadians, with a 22% reduction. The research also identified specific trainability genes linked to the decline in cardiorespiratory fitness among female survivors.
Researchers have discovered a new treatment approach for T-cell acute lymphoblastic leukemia (T-ALL) that targets the Notch signaling pathway with greater safety and efficacy than previous treatments. The findings, published in Science Translational Medicine, show promise for translating this therapy to patients.
Scientists at Johns Hopkins University have unraveled how the DNA machinery fits together, revealing a paradigm shift in understanding genetic illness. The discovery of how nucleosomes change shape to bind with an enzyme could unveil new treatment opportunities for childhood leukemia.
Researchers have shed light on how leukemia cells become resistant to drugs and describe a potential solution using two drugs in combination. The study identifies the genes responsible for resistance, revealing that cancer cells overcome the lack of asparagine by breaking down proteins.
Scientists identify CXCL12-expressing mesenchymal stromal cell niches as a strategy to target and eliminate treatment-resistant leukemic stem cells in chronic myelogenous leukemia. The study reveals that these niche interactions control quiescence of leukemic stem cells.
Researchers at Tel Aviv University developed a novel biosensor that can isolate and target leukemic stem cells, the most malignant of all leukemic cells. The sensor uses genetic encoding to identify and characterize these cells, which have high regenerative potential and escape targeted therapies.
Scientists at CeMM Research Center have developed a method to identify promising drug combinations for chronic lymphocytic leukemia. By combining epigenetic analysis and high-throughput imaging, researchers can predict which drugs are likely to work together effectively, reducing trial-and-error approaches.
A new study from Instituto Gulbenkian de Ciencia shows that leukemia can emerge as a consequence of prolonged precursor cells in the thymus. This blood cancer affects mostly children and is associated with a high risk of developing T-cell acute lymphoblastic leukemia.
Researchers discovered that STAT5B facilitates leukemogenesis in B-cell acute lymphocytic leukemia. They found that the absence of STAT5B increases interferon response and suppresses transformation. This understanding may enable precision medicine strategies to treat disease.
A new study led by St. Jude Children's Research Hospital found that high-risk leukemia patients did not experience improved long-term survival with bone marrow transplantation. Treatment guided by measuring minimal residual disease was associated with better outcomes, with 58% of patients becoming long-term survivors.
St. Jude Children's Research Hospital scientists identify 23 subtypes of B-cell acute lymphoblastic leukemia (B-ALL), including eight new subtypes, with distinct genomic and clinical features. The study's findings may lead to the development of precision medicines and customized treatments for high-risk patients.
Acute lymphoblastic leukemia (ALL) researchers find bone marrow stromal cells harbor leukemia cells, shielding them from chemotherapy. Yong-Mi Kim seeks integrin molecules to block treatment evasion.